Skip to main content
ANGLE PLC logo

ANGLE PLC — Investor Relations & Filings

Ticker · AGL ISIN · GB0034330679 LEI · 213800BY11K6W3NMS374 IL Human health and social work activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country GB United Kingdom
Listing IL AGL

About ANGLE PLC

https://angleplc.com/

ANGLE PLC is a liquid biopsy company that has developed the proprietary Parsortix® system for cancer diagnostics and research. The system uses a patented, size-based microfluidic technology to capture and harvest intact, live circulating tumor cells (CTCs) and CTC clusters from patient blood for downstream analysis. The company's commercial offerings are focused on two main areas: diagnostic products and clinical services. Products include the FDA-cleared, automated Parsortix PC1 instrument and its associated single-use cassettes for use in clinical laboratories. The company also provides global laboratory services from its GCP-compliant facilities, supporting biopharmaceutical companies and translational research projects with complete CTC harvesting and analysis solutions. These applications aid in drug development, patient monitoring, and the advancement of personalized medicine in oncology.

Recent filings

Filing Released Lang Actions
Confirmation of Q1 trading update
Regulatory Filings
2026-04-30 English
Research Collaboration with The Royal Marsden
Regulatory Filings Classification · 1% confidence The document is an RNS announcement (Regulatory News Service) distributed via the London Stock Exchange’s Primary Information Provider. It describes a research collaboration with The Royal Marsden NHS Foundation Trust, contains no financial results, management changes, dividend notices, or other specialized filings (e.g., earnings release, board changes, M&A, share issues, etc.). It is a general regulatory announcement of corporate news. Therefore it falls under the fallback category “Regulatory Filings (RNS).”
2026-04-20 English
Aligning Regulatory Approach with Commercial Needs
Regulatory Filings
2026-02-13 English
Preliminary Fourth Quarter 2025 Financial Results
Earnings Release Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from CelLBxHealth plc providing preliminary, unaudited financial results for the fourth quarter and full year 2025. It includes key financial highlights (revenue, cash position), operational updates (cost rationalization, delisting from OTCQX), and forward-looking statements. Because it is an initial announcement of financial results containing key highlights rather than the full audited annual report, it is classified as an Earnings Release (ER). Q4 2025
2026-01-16 English
Board changes
Board/Management Information Classification · 1% confidence The document is an official announcement from CelLBxHealth plc regarding changes to its Board of Directors, specifically the appointment of a new CEO and several Non-Executive Directors, as well as the departure of an existing Non-Executive Director. The text explicitly uses the header 'Board changes' and provides the required regulatory disclosures under AIM Rules for Companies. This fits the definition of a Board/Management Information filing.
2026-01-12 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details the acquisition of voting rights by Conifer Management, L.L.C. in CelLBxHealth plc, crossing a specific threshold (29.9%). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which tracks changes in significant share ownership levels.
2025-12-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.